Hormonal
SGLT2 inhibitors lower blood glucose by inhibiting renal glucose reabsorption, resulting in glucosuria, with efficacy dependent on maintaining a filtered glucose load above 80g/day.
SGLT2 inhibitors are effective for lowering blood sugar by helping your kidneys excrete excess glucose, but they only work well if your blood sugar is high enough and your kidneys are functioning adequately. They also offer heart and kidney protection. You must take them as prescribed and maintain good hygiene to minimize infection risks.
The induction of glucosuria leads to improved glycemic control in all stages of T2DM, with a low risk of hypoglycemia, because they stop working when the filtered glucose load drops below 80 g per day without interfering with metabolic counter regulation [8].
Why this rating
Supported by multiple large-scale clinical trials (EMPA-REG, CANVAS, DECLARE-TIMI 58) cited in the review.
Source
Modern Challenges in Type 2 Diabetes: Balancing New Medications with Multifactorial Care
Alfredo Caturano et al. · Biomedicines · 2024
DOI 10.3390/biomedicines12092039
More from this paper
- GLP-1 Receptor Agonists (GLP-1RAs) improve glycemic control and promote weight loss by enhancing glucose-dependent insulin secretion, inhibiting glucagon, slowing gastric emptying, and reducing appetite via central nervous system pathways.Good
- Tirzepatide, a dual GIP/GLP-1 receptor agonist, provides superior glycemic control and weight loss compared to monotherapy by leveraging synergistic mechanisms of both incretin hormones.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →